Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis

Amyotrophic Lateral Sclerosis Clinical Trial

— ROSA  

Official title:

Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06083584
• Other study ID #: NIMAO/LOCAL/2023/CG-01
• Status: Recruiting
• Start date: November 22, 2023
• Est. completion date: May 2025

Study information

• Verified date: January 2024
• Source: Centre Hospitalier Universitaire de Nimes
• Contact: Claire Guissart
• Phone: 04 66 68 32 07
• Email: claire.guissart[@]chu-nimes.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Genetic diagnosis of Amyotrophic Lateral Sclerosis (ALS) could identify the origin of the disease, potentially allowing the patient to pursue targeted/gene therapy. However, many familial forms of ALS are genetically undiagnosed, either because no variant has been detected in the genes of interest, or because the detected variant(s) have uncertain significance. Currently, molecular diagnosis takes place in two stages: 1) Search for the GGGGCC expansion in the C9ORF72 gene by RP-PCR; 2) Analysis of the coding regions by high-throughput sequencing of a panel of 30 genes involved in ALS.

Many of these variants of uncertain significance affect splicing. Their impact can be predicted using in silico tools, but only an analysis of the patient's RNA can confirm their pathogenic nature. Currently, the analysis of transcripts is only done a posteriori, when a variant predicted to impact splicing is detected on the patient's DNA. RT-PCR followed by Sanger sequencing then verifies the impact of the splice variants. This method confirmed the impact of certain splice variants in patients. However, this method is time-consuming and requires custom development, and is mutation/gene/patient-dependent. In contrast, high-throughput RNA sequencing (RNA-Seq) simultaneously analyzes the splicing of numerous genes, with a global approach, applicable to all patients. This approach avoids the custom design of primers, which can be biased by the interpretation of splicing predictions, while RNA-Seq systematically captures and sequences all the transcripts. Finally, RNA-Seq provides additional information compared to DNA sequencing such as the detection of exon skipping, intron inclusion, and the creation of fusion transcripts.

In the GTEx project (GTEx Consortium, 2013), expression levels of human genome transcripts were quantified by RNA-Seq. Using these results, the study investigators measured expression of transcripts of known ALS genes in whole blood. Applying a threshold value of 0.5 transcripts per million reads (TPM), 25 of the 30 ALS genes currently analyzed by NGS in routine diagnostics at Nîmes University Hospital could be eligible for a complete analysis by RNA-Seq. None of the French laboratories carrying out genetic analyzes of ALS has yet developed RNA-Seq as a routine diagnostic tool. The study laboratory receives more than 600 requests for genetic diagnosis of ALS patients per year. The aim of this study is therefore to develop a global method for analyzing RNA transcripts of ALS genes to categorize the mutations to improve the diagnostic management of patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 192
• Est. completion date: May 2025
• Est. primary completion date: May 2025
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Have a prescription for a genetic diagnosis of ALS (or familial hypercholesterolemia for the control cohort)

• Have given their informed consent for the genetic study and the biobank

• The patient must be a member or beneficiary of a health insurance plan

Exclusion Criteria:

• The patient is under safeguard of justice or state guardianship

Related Conditions & MeSH terms

• Amyotrophic Lateral Sclerosis
• Motor Neuron Disease
• Sclerosis

Intervention

Other:
• RNA sequencing
RNA-Seq (Sureselect XT HS2 RNA) from patient blood sample

Locations

Country	Name	City	State
France	CHU de Bordeaux	Bordeaux
France	CHU de Clermont-Ferrand	Clermont-Ferrand
France	CHU de Lyon	Lyon
France	La Timone	Marseille
France	CHU de Montpellier	Montpellier
France	CHU de Nîmes	Nîmes
France	CHU de Toulouse	Toulouse

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nimes	Association pour la Recherche sur la Sclérose Latérale Amyotrophique et autres maladies du motoneurones

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Concordance between the RNA-Seq results (index text) versus RT-PCR followed by Sanger sequencing (reference technique) on positive plus negative controls	Sashimi Plot visualized in Integrative Genomics Viewer	Day 0
Secondary	Frequency of splicing anomalies detected in ALS patients in the "exploratory cohort" versus negative controls.	Frequency	Day 0